

PATIENT INFORMATION

Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal

Patient Full Name: _____ DOB: _____ Phone: _____ Gender: ☐ M ☐ F ☐ Other

Email Address: _____ Address: _____ Weight (lbs/kg): _____ Height (in): _____

☐ NKDA Allergies: _____ Existing prior authorization? ☐ Yes, (Send a copy) ☐ No (AIC will process)

Patient Status: ☐ New to Therapy ☐ Continuing Therapy Last Treatment Date: _____ Next Due Date: _____

Patient Preferred Location: _____

DIAGNOSIS & CLINICAL INFORMATION

ICD 10-Code & Description (Provide full completed code)

☐ M04.1 Periodic fever syndromes (e.g. FMF, TRAPS, HIDS/MKDS)

☐ M08.2 (series): Systematic juvenile idiopathic arthritis (SJIA)

☐ M04.2 Cryopyrin-associated periodic syndromes (CAPS)

☐ Other: _____

☐ M06.1 Adult-onset Still's disease (AOSD)

REQUIRED DOCUMENTATION: Please include insurance card (front & back), all patient demographics, history & physicals, medication lists, recent lab results (CBC, CMP, TB, Hep B panel-depending on medication), signed prescription order and recent visit notes.

Confirm that these and the required lab orders have been sent to American Infusion Care and necessary parties.

PRESCRIPTION INFORMATION

Nursing: Provide nursing care per American Infusion Care - Specialty Infusions protocols, including reaction management and post-procedure observation

Pre-Medications

☐ Acetaminophen (Tylenol) ☐ 500mg ☐ 650mg ☐ 1000mgPO

☐ Cetirizine (Zyrtec) 10mgPO

☐ Loratadine (Claritin) 10mgPO

☐ Diphenhydramine (Benadryl) ☐ 25mg ☐ 50mg ☐ PO ☐ IV

☐ Methylprednisolone (Solu-Medrol) ☐ 40mg ☐ 125mg IV

☐ Other: _____ Dose: _____ Route: _____

Lab Orders

Required: TB results within 1 year

☐ Other: _____

Ilaris (canakinumab) (Select one):

For Still's Disease including Adult Onset Still's Disease and Systemic Juvenile Idiopathic Arthritis.

☐ 4mg/kg (with a max of 300mg) for patients with a body weight greater than or equal to 7.5kg subcutaneous every 4 weeks

☐ Other: _____

For Cryopyrin-Associated Periodic Syndromes (CAPS)

☐ 150mg for patients with body weight greater than 40kg subcutaneous every 8 weeks

☐ 2mg/kg for patients with body weight greater than or equal to 15kg and less than or equal to 40kg subcutaneous every 8 wks

☐ Other: _____

For Tumor Necrosis Factor Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency, Familial Mediterranean Fever

Body weight less than or equal to 40kg

☐ 2mg/kg subcutaneous every 4 weeks ☐ 4mg/kg subcutaneous every 4 weeks - consider if clinical response not adequate.

☐ Other: _____

Body weight greater than 40kg

☐ 150mg subcutaneous every 4 weeks ☐ 300mg subcutaneous every 4 weeks - consider if clinical response not adequate.

☐ Other: _____

Gout Flares ☐ 150 mg subcutaneously 1 dose

☐ Refills: ☐ zero ☐ 6 months ☐ 12 months ☐ _____ (Prescription valid for one year, unless otherwise indicated)

Post Treatment Observations: The patient is ☐ not required / ☐ required to stay for 30 minutes following the first administration.

Special Instructions: _____

PROVIDER INFORMATION

Provider Full Name: _____ Provider NPI #: _____ Specialty: _____

Practice Address: _____ City: _____ State: _____ Zip Code: _____

Contact Name: _____ Phone: _____ Fax: _____ Email: _____

Provider Name (Print)

Provider Signature

Date